Avalon Investment & Advisory’s Adaptive Biotechnologies ADPT Stock Holding History

Avalon Investment & Advisory’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$585K	Sell	66,293 -8,362	-11%	-$73.7K	0.02%	238
2022 Q4	$570K	Buy	74,655 +11,954	+19%	+$93K	0.02%	243
2022 Q3	$446K	Buy	62,701 +19,032	+44%	+$179K	0.01%	238
2022 Q2	$353K	Buy	43,669 +20,257	+87%	+$178K	0.01%	254
2022 Q1	$325K	Buy	23,412 +7,370	+46%	+$116K	0.01%	276
2021 Q4	$450K	Sell	16,042 -10,879	-40%	-$333K	0.01%	255
2021 Q3	$915K	Buy	26,921 +407	+2%	+$14.7K	0.02%	246
2021 Q2	$1.08M	Buy	26,514 +5,931	+29%	+$231K	0.02%	234
2021 Q1	$829K	Buy	20,583 +4,059	+25%	+$220K	0.02%	254
2020 Q4	$977K	Buy	16,524 +4,787	+41%	+$247K	0.02%	248
2020 Q3	$571K	Buy	+11,737	New	+$493K	0.01%	257

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Avalon Investment & Advisory's ADPT Position: Q1 2023 in Review

Avalon Investment & Advisory reduced its Adaptive Biotechnologies (ADPT) stake by 11% in Q1 2023, selling an estimated $73.7K and leaving 66,293 shares worth $585K. The position accounts for 0.02% of the portfolio, ranked #238.

Avalon Investment & Advisory first reported a position in ADPT in Q3 2020 and has held it in 11 quarters since. The position peaked at $1.08M in Q2 2021. 226 funds tracked by Wall St. Rank hold ADPT as of Q1 2023.

Avalon Investment & Advisory held 66,293 shares of Adaptive Biotechnologies worth $585K as of Q1 2023.
Avalon Investment & Advisory sold 8,362 Adaptive Biotechnologies shares in Q1 2023, an estimated $73.7K.
Adaptive Biotechnologies made up 0.02% of Avalon Investment & Advisory's portfolio in Q1 2023, its #238 holding.
Avalon Investment & Advisory first reported a position in Adaptive Biotechnologies in Q3 2020 and has held it in 11 quarters since.
Avalon Investment & Advisory's Adaptive Biotechnologies position peaked at $1.08M in Q2 2021.
226 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2023.

Based on Avalon Investment & Advisory's 13F filing for Q1 2023, filed 15 May 2023.